P PROTAGONIST THERAPEUTICS INC
| Market Cap | $6.62B |
| P/E Ratio | — |
| Forward P/E | -239.00 |
| Dividend Yield | — |
| Beta | 2.11 |
| 52W Range | $40.89 - $105.40 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.01% | $1.78M | 20,349 | Add 0.12% |
Insider Trading
| Insider Name of the company insider who made the trade 26 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| MOLINA ARTURO MDChief Medical Officer | Sale | 15,000 | $104.79 | $1.57M | 26 Mar 2026 | 26 Mar 2026 |
| Ali AsifChief Financial Officer | Sale | 24,765 | $104.24 | $2.58M | 26 Mar 2026 | 26 Mar 2026 |
| SELICK HAROLD E | Sale | 24,000 | $105.00 | $2.52M | 26 Mar 2026 | 26 Mar 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 54,641 | $101.00 | $5.52M | 25 Mar 2026 | 23 Mar 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 59 | $101.00 | $5.96K | 24 Mar 2026 | 23 Mar 2026 |
| Williams Lewis T | Sale | 18,000 | $82.42 | $1.48M | 17 Feb 2026 | 18 Feb 2026 |
| Waddill William D. | Sale | 20,000 | $83.68 | $1.67M | 06 Feb 2026 | 06 Feb 2026 |
| William D. WaddillDirector | Sale | 20,000 | $83.68 | $1.67M | 06 Feb 2026 | 06 Feb 2026 |
| Ali AsifChief Financial Officer | Sale | 18,203 | $83.14 | $1.51M | 27 Jan 2026 | 27 Jan 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 4,068 | $83.19 | $338.42K | 27 Jan 2026 | 27 Jan 2026 |
| MOLINA ARTURO MDChief Medical Officer | Sale | 5,000 | $82.00 | $410.00K | 27 Jan 2026 | 27 Jan 2026 |
| Ali AsifChief Financial Officer | Sale | 28,000 | $83.13 | $2.33M | 27 Jan 2026 | 27 Jan 2026 |
| MOLINA ARTURO MDChief Medical Officer | Sale | 5,000 | $82.28 | $411.40K | 26 Jan 2026 | 27 Jan 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 14,205 | $84.05 | $1.19M | 26 Jan 2026 | 27 Jan 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 10,685 | $84.00 | $897.54K | 26 Jan 2026 | 27 Jan 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 19,315 | $84.59 | $1.63M | 23 Jan 2026 | 27 Jan 2026 |
| MOLINA ARTURO MDChief Medical Officer | Sale | 13,151 | $82.42 | $1.08M | 23 Jan 2026 | 27 Jan 2026 |
| MOLINA ARTURO MDChief Medical Officer | Sale | 9,514 | $82.48 | $784.71K | 20 Jan 2026 | 21 Jan 2026 |
| Ali AsifChief Financial Officer | Sale | 8,588 | $82.48 | $708.34K | 20 Jan 2026 | 21 Jan 2026 |
| PATEL DINESH V PH DPresident and CEO | Sale | 34,438 | $82.48 | $2.84M | 20 Jan 2026 | 21 Jan 2026 |
| MOLINA ARTURO MDChief Medical Officer | Sale | 2,712 | $84.77 | $229.90K | 17 Nov 2025 | 19 Nov 2025 |
| Arturo Molina MDChief Medical Officer | Sale | 2,712 | $84.77 | $229.90K | 17 Nov 2025 | 19 Nov 2025 |
| Waddill William D. | Sale | 8,000 | $87.81 | $702.48K | 10 Oct 2025 | 14 Oct 2025 |
| Waddill William D. | Sale | 4,000 | $69.25 | $277.00K | 10 Oct 2025 | 14 Oct 2025 |
| William D. WaddillDirector | Sale | 8,000 | $87.81 | $702.48K | 10 Oct 2025 | 14 Oct 2025 |
| William D. WaddillDirector | Sale | 4,000 | $69.25 | $277.00K | 10 Oct 2025 | 14 Oct 2025 |
Frequently Asked Questions
What is PTGX stock price today?
PROTAGONIST THERAPEUTICS INC (PTGX) is currently trading at $103.78. The stock has a 52-week range of $40.89 to $105.40 and a market capitalization of $6.62B.
Is PTGX a good stock to buy in 2026?
PROTAGONIST THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +123.2%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling PTGX stock?
There have been 26 insider transactions for PTGX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has PTGX stock performed over the past year?
PROTAGONIST THERAPEUTICS INC (PTGX) has returned +123.2% over the past 12 months. The stock traded between $40.89 and $105.40 during this period, and is currently at $103.78.
Which hedge funds own PTGX (PROTAGONIST THERAPEUTICS INC)?
1 tracked hedge funds currently hold PTGX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is PTGX's market cap and valuation?
PROTAGONIST THERAPEUTICS INC (PTGX) has a market capitalization of $6.62B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is PTGX's revenue and profitability?
PROTAGONIST THERAPEUTICS INC reported revenue of $46.02M with net income of N/A and a profit margin of N/A. The stock has a beta of 2.11.
What sector is PTGX in and who are its biggest institutional holders?
PROTAGONIST THERAPEUTICS INC (PTGX) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.